Am I a Good Candidate for esketamine (Spravato)? The Two Clinical Pathways That Qualify You
You may be a candidate for esketamine (Spravato) if you are an adult with treatment-resistant depression — meaning you have not responded adequately to at least two oral antidepressants — or if you have major depressive disorder with active suicidal ideation or behavior, both of which require evaluation and ongoing psychiatric care at a certified treatment center like Lumin Health.
If you are reading this, you are likely not here out of casual curiosity. You have probably tried multiple medications. You may have waited weeks or months for each one to work, adjusted doses, switched classes, tolerated side effects that made daily life harder — and still found yourself in the same place. That experience is not a personal failure. It is a clinical reality that affects roughly one in three adults treated for depression, and it is precisely the population esketamine (Spravato) was designed to reach.
This guide is built to give you something most eligibility pages do not: a genuinely specific framework for understanding whether you qualify, what medical conditions might complicate candidacy, and why the insurance authorization process itself requires clinical expertise to navigate. We are not going to tell you to "talk to your doctor" without first telling you what, exactly, to talk about.
The Two FDA-Approved Indications for esketamine (Spravato)
Esketamine (Spravato) carries FDA approval for two distinct patient populations. Understanding which pathway applies to you is the first step in determining candidacy — and it has direct implications for how your insurance company processes coverage.
Pathway 1: Treatment-Resistant Depression (TRD)
The clinical definition of TRD is depression that has not responded to at least two adequate courses of antidepressant treatment. "Adequate" here means the medication was taken at a therapeutic dose for a sufficient duration — typically six to eight weeks per trial. If you tried a low dose of sertraline for three weeks before switching, most insurers and clinicians would not count that as a full trial.
The antidepressants in question generally fall within the monoamine neurotransmitter classes — SSRIs, SNRIs, NDRIs, NASAs, and others targeting serotonin, norepinephrine, and dopamine. These medications work for many people. But the clinical literature shows that each successive antidepressant trial carries a diminishing probability of response. By the third or fourth attempt, remission rates can fall below 15 percent.
If you have reached that point, you are not running out of options. You are reaching a category of treatment — specifically, glutamate-based intervention — that operates through a fundamentally different mechanism than anything you have tried before. Esketamine does not modulate serotonin reuptake. It acts on the glutamate system, the brain's primary excitatory pathway, triggering downstream release of Brain-Derived Neurotrophic Factor (BDNF) and promoting the formation of new synaptic connections. This is not a refinement of the same approach. It is a different approach entirely.
Pathway 2: Major Depressive Disorder with Active Suicidal Ideation (MDDSSI)
The second approved indication is for adults with major depressive disorder accompanied by acute suicidal thoughts or behavior. This is a critical distinction, and one that many patients and even some referring providers do not fully understand.
"If you're experiencing suicidal thoughts with depression, the insurance companies will cover esketamine (Spravato) without needing to have not responded to prior antidepressant trials. You don't need to have taken any other requisite number of antidepressants."
Under the MDDSSI pathway, the requirement to have not responded to two prior antidepressants does not apply. If your depression is accompanied by active suicidal ideation, you may qualify for esketamine (Spravato) coverage even if this would be your first treatment beyond a single antidepressant — or even alongside your current medication. The severity and acuity of the presentation, not the length of your medication history, is what opens this pathway. Depression severity is measured using validated rating scales; at Lumin Health, we use the MADRS (Montgomery-Åsberg Depression Rating Scale) to establish clinical eligibility.
Why Insurance Authorization Is More Complicated Than the Clinical Criteria
Here is where many patients encounter an invisible wall. The FDA's indications are relatively clear. But each insurance company layers its own operational definition of TRD on top of the clinical one — and these definitions vary in ways that can determine whether your prior authorization is approved or denied.
Some insurers require documentation that at least two antidepressants from different classes were tried. Others accept two trials from the same class. Some mandate a specific minimum duration per trial. Others require that augmentation strategies — such as adding lithium, an atypical antipsychotic, or thyroid hormone — were attempted before esketamine is considered. And the documentation format, the rating scale scores, and the clinical notes required to support the request differ from plan to plan.
This complexity is not a reason to be discouraged. It is a reason to work with a practice that has deep, specific expertise in this process. At Lumin Health, our team navigates these authorization pathways daily. We understand the nuances of how Aetna defines TRD differently from Blue Cross Blue Shield, how United Healthcare structures its review criteria, and how to present clinical documentation in the format each payer requires. We verify your insurance eligibility upfront and explain what your coverage looks like before you begin treatment.
Additionally, depending on your insurance plan, esketamine (Spravato) may be delivered through a "pharmacy benefit" — where a specialty pharmacy ships the medication directly to our practice specifically for you — or through a "Buy and Bill" structure, where the practice stocks the medication and bills your insurer. Each pathway has its own authorization requirements, and each insurance company adds further nuance. This is part of why expertise matters.
Absolute Contraindications: When esketamine (Spravato) Is Not Safe
Candidacy is not only about whether your depression qualifies. It is also about whether esketamine can be administered safely given your medical history. The following conditions represent absolute contraindications — situations where the risks of esketamine (Spravato) are considered unacceptable regardless of the severity of your depression:
- Aneurysmal vascular disease: An existing aneurysm in any blood vessel, including cerebral aneurysms. Esketamine can transiently raise blood pressure, and this increase poses a rupture risk.
- Arteriovenous malformation (AVM): An abnormal connection between arteries and veins, particularly in the brain. The same hemodynamic concerns apply.
- History of intracerebral hemorrhage: A prior bleed within the brain tissue itself. The transient blood pressure elevation during treatment creates unacceptable risk of recurrence.
- Known allergy to esketamine or ketamine: Any prior allergic reaction to either compound rules out use of esketamine (Spravato) entirely, as esketamine is the S-enantiomer of the ketamine molecule.
If any of these apply to you, esketamine is not appropriate. However, depending on the nature of your condition and your treatment history, other options — including intramuscular (IM) ketamine therapy in some cases, or alternative treatment strategies — may still be worth exploring with a qualified psychiatrist.
"I Have [X Condition] — Can I Still Be a Candidate?"
Beyond absolute contraindications, there are several medical conditions that require careful evaluation but do not automatically disqualify you. These are clinical flags that call for thoughtful planning, not hard stops.
Hypertension
Esketamine can cause a transient increase in blood pressure during and immediately after treatment. For patients with well-controlled hypertension — meaning blood pressure is managed with medication and readings remain steadily within target range — esketamine (Spravato) treatment is generally feasible with appropriate monitoring. At Lumin Health, we monitor blood pressure continuously during and after every session. Uncontrolled hypertension, however, must be addressed and stabilized before treatment can begin. We collaborate with your primary care provider or cardiologist to ensure cardiovascular safety before and throughout your treatment course.
Liver Disease
Esketamine is metabolized by the liver. Patients with mild to moderate hepatic impairment may require additional monitoring, and the duration of post-dose observation may need to be extended, as the medication may take longer to clear the system. Severe liver disease introduces more significant concerns and requires a detailed risk-benefit discussion. Your hepatic function should be part of the screening conversation before treatment is initiated.
History of Psychosis
Esketamine can produce dissociative and perceptual effects, which in individuals with a current or recent history of psychotic symptoms — such as those seen in schizophrenia or schizoaffective disorder — may be destabilizing. This does not mean a distant history of a single psychotic episode is automatically disqualifying, but it does mean the evaluation must be thorough. Active psychosis is a contraindication. A remote history warrants careful discussion about current psychiatric stability, the presence of protective factors, and the risk-to-benefit ratio for that specific individual.
Bipolar Disorder
Research into ketamine for depression in patients with bipolar disorder is ongoing, and initial data show promise. However, there is a theoretical concern that esketamine could precipitate a manic or hypomanic episode. If you have bipolar depression, your treatment plan must include mood-stabilizing medication, and your clinical team must be equipped to monitor for early signs of mood elevation. This is an area where the prescribing psychiatrist's familiarity with both the medication and the condition matters enormously.
Substance Use History
A history of substance use does not automatically exclude you from esketamine (Spravato) candidacy. Esketamine is classified as a Schedule III controlled substance, and the REMS (Risk Evaluation and Mitigation Strategy) program mandates that all treatment occurs in a certified healthcare setting under direct supervision — precisely to mitigate risk. What matters clinically is where you are in your recovery, the stability of your current situation, and whether the treatment team can provide the appropriate level of support. People with histories of substance dependence — opioid or other — should speak with providers about where they are in recovery. It can help cue the provider to be sensitive to what a person's history means for their care, and help us deliver care safely.
Pregnancy
Pregnancy is a contraindication for esketamine (Spravato). Esketamine readily crosses the placenta, and the effects of repeated exposure on a developing fetus are unknown and should not be risked. If you are planning to become pregnant, discuss the timing of any treatment with your provider to ensure safety.
How Lumin Health Evaluates Candidacy: The Screening Process
At Lumin Health, determining candidacy is not a checkbox exercise. It is a clinical conversation — one that considers not just your diagnosis, but your full medical history, your medication timeline, your goals for treatment, and your readiness to engage.
- Initial evaluation with a psychiatrist or psychiatric nurse practitioner. Every patient who begins care at Lumin Health meets with a prescribing clinician — not a coordinator, not an intake specialist. The clinician reviews your psychiatric and medical history, your prior medication trials, and your current symptom severity using validated instruments like the MADRS.
- Insurance verification and prior authorization. Our team contacts your insurer, confirms your plan's specific requirements for esketamine (Spravato) coverage, and submits the prior authorization request with the clinical documentation required. We explain your expected out-of-pocket costs before treatment begins.
- Medical safety screening. Blood pressure, cardiovascular history, hepatic function, substance use history, pregnancy status, and any history of psychosis or mania are reviewed. If additional information is needed from your primary care provider or specialist, we coordinate that directly.
- Treatment planning and goal alignment. Before your first dose, we discuss what to expect during sessions — including the expected dissociative effects, the two-hour mandatory observation period, and the transportation requirement (you cannot drive the day of treatment). We work with you to align the treatment schedule with your life and ensure adequate support structures are in place.
- First treatment session. You self-administer the nasal spray under clinical supervision. Your vital signs are monitored throughout. The clinical team is present to manage any side effects — nausea, dizziness, increased blood pressure, or emotional intensity — and to provide reassurance and support during the dissociative experience.
The Neuroscience of Why This Matters
If you have tried two, three, or four antidepressants and none have worked, the problem is not a lack of effort or willpower. The problem may be that every medication you have tried has been targeting the same neurochemical system — serotonin, norepinephrine, and dopamine — while the underlying rigidity in your brain's patterns has remained untouched.
Depression, particularly the treatment-resistant form, is increasingly understood as a disorder of connectivity and flexibility. The Default Mode Network (DMN) — the brain's self-referential processing system, the part that generates your internal narrative — can become hyperactive and rigid, trapping you in cycles of rumination and negative self-attribution. Thought patterns become entrenched. Reward circuits lose sensitivity. The sense of futility becomes hardwired rather than situational.
Esketamine (Spravato) acts on this system differently. By modulating glutamate transmission, it triggers a cascade that includes BDNF release and the formation of new synaptic connections — a process called neuroplasticity. Research has shown that both racemic ketamine and esketamine demonstrate significant efficacy in treatment-resistant populations, with response often observable within days rather than weeks. The DMN quiets. The rigid patterns loosen. And for a period of time — often described as a 48-to-72-hour neuroplasticity window — the brain becomes more receptive to forming new, healthier patterns of thought and behavior.
"Ketamine acts on glutamate, which is entirely different from the serotonin system that SSRIs target. That's why it can work for people who haven't responded to traditional antidepressants."
This is not a cosmetic distinction. It is the reason esketamine (Spravato) exists as a separate treatment category — and the reason candidacy for it is defined by what has not worked, not by what is wrong with you.
What Happens If You Are Not a Candidate
Not everyone who wants esketamine (Spravato) will qualify — and that is not a dead end. At Lumin Health, we also provide intramuscular (IM) ketamine treatment, which uses a racemic mixture of both S-ketamine and R-ketamine and does not require FDA-specific indication criteria or the same insurance authorization pathways. IM ketamine sessions cost $500 per session. Most commercial insurers do not cover off-label ketamine for depression, but Lumin Health provides a Superbill for patients with out-of-network PPO benefits to submit for potential partial reimbursement.
If neither pathway is appropriate — due to medical contraindications, timing, or other factors — we will tell you clearly and help you understand what alternative next steps might look like. One of the most respectful things a practice can do is say "not yet" when the circumstances require it.
Frequently Asked Questions
How many antidepressants do I need to have tried to qualify for esketamine (Spravato)?
For the TRD pathway, you must have had an inadequate response to at least two oral antidepressants taken at adequate doses for adequate durations. For the MDDSSI pathway — depression with active suicidal ideation — no prior lack of response to antidepressants is required.
Does Lumin Health accept my insurance for esketamine (Spravato)?
Lumin Health accepts most major insurers in Massachusetts, including Aetna, Anthem, Blue Cross Blue Shield, Cigna, Harvard Pilgrim, United Healthcare, and Medicare. With insurance, cost typically aligns with a standard office visit co-pay. Check your specific coverage at lumin.health/insurance-we-accept.
Can I receive esketamine (Spravato) if I am currently taking an antidepressant?
Yes. Esketamine (Spravato) is designed to be used alongside an oral antidepressant. Your current antidepressant regimen can typically continue during treatment, though your clinician will review your full medication list to ensure there are no specific interactions that need to be addressed.
What does the esketamine (Spravato) experience feel like?
Most patients experience some degree of dissociation — a temporary feeling of detachment or altered perception — along with possible dizziness, nausea, or a sense of lightness. These effects are expected, time-limited, and clinically supported. You will be monitored for at least two hours after each dose, and you cannot drive for the remainder of the day following treatment.
Where is Lumin Health located?
Lumin Health is based out of the Boston Metro area and expanding to other states. If you are not local to Massachusetts, this guide is designed to help you understand exactly what to discuss with a qualified provider in your area. For those within reach of our practice, we would be grateful to walk with you toward relief. Learn more about esketamine (Spravato) treatment at Lumin Health.
You've read the science. Now take the next step.
Lumin Health provides safe, expert-administered ketamine and Spravato treatment across Massachusetts and the greater Washington DC/Maryland area. Your journey starts with a free, no-commitment intro call.
Available in Massachusetts and the greater Washington DC/Maryland area.
.svg)
